CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 126,051	$ 140,866	$ 248,233	$ 278,413	$ 537,840
Cost of revenues	34,018	28,503	63,632	56,230	114,867
Gross profit	92,033	112,363	184,601	222,183	422,973
Operating costs and expenses:
Research, development and clinical studies	55,427	57,075	115,131	99,309	206,085
Sales and marketing	58,488	44,750	109,657	82,634	173,658
General and administrative	40,778	31,666	82,722	62,174	132,753
Total operating costs and expenses	154,693	133,491	307,510	244,117	512,496
Operating income (loss)	(62,660)	(21,128)	(122,909)	(21,934)	(89,523)
Financial income (expenses), net	8,756	(2,228)	17,925	(3,937)	7,677
Income (loss) before income tax	(53,904)	(23,356)	(104,984)	(25,871)	(81,846)
Income tax	3,514	652	5,495	2,784	10,688
Net income (loss)	$ (57,418)	$ (24,008)	$ (110,479)	$ (28,655)	$ (92,534)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.54)	$ (0.23)	$ (1.04)	$ (0.27)	$ (0.88)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.54)	$ (0.23)	$ (1.04)	$ (0.27)	$ (0.88)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	106,289,073	104,627,789	105,979,791	104,408,164	104,660,476
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	106,289,073	104,627,789	105,979,791	104,408,164	104,660,476